Citizens JMP lowered the firm’s price target on PolyPid (PYPD) to $14 from $16 and keeps an Outperform rating on the shares after the company announced that it anticipates gross proceeds of $26.7M from the exercise of 7.6M existing warrants that have been re-priced to a $3.50 exercise price and that it will issue another 7.6M warrants at $4.50. The firm’s confidence is bolstered in the potential for D-PLEX100 to get to market following the warrant exercise, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- PolyPid price target raised to $13 from $11 at H.C. Wainwright
- PolyPid’s D-PLEX100: Compelling Phase 3 Results and Strong Commercial Prospects Justify Buy Rating
- PolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II Trial
- PolyPid announces topline results from Phase 3 SHIELD II trial
- Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls